Abeona Therapeutics Announces Upcoming Conference Participation
September 22 2017 - 8:45AM
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel gene
therapies for life-threatening rare genetic diseases, today
announced the Company’s senior management team and clinical
partners will participate in the following investor and industry
conferences:
Cantor Fitzgerald Global Healthcare
ConferenceDate: Monday, September 25th Presentation
time: 2:25 PM ET Location: New York City, NYWebcast:
http://wsw.com/webcast/cantor6/abeo/
Cell & Gene Meeting on the
MesaDate: October 4th-6thLocation: La Jolla, CAWebsite:
www.meetingonthemesa.com
The Jefferies 2017 Gene Therapy
Summit Date: Thursday, October 12th Presentation time:
11:30 AM ETLocation: New York City, NY
The European Society of Gene and Cell
Therapy (ESGCT)Date: October 17th-20thLocation: Berlin,
Germany Website: www.esgct.eu
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an
adeno-associated virus (AAV) based gene therapy for Sanfilippo
syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts)
for recessive dystrophic epidermolysis bullosa (RDEB). Abeona
is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type
B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten
disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile
Batten disease (INCL), EB-201 for epidermolysis bullosa (EB),
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
proprietary vector platform, AIM™, for next generation product
candidates. For more information, visit
www.abeonatherapeutics.com.
Investor Contact: Christine Silverstein Vice
President, Investor Relations Abeona Therapeutics Inc. +1 (212)
786-6212 csilverstein@abeonatherapeutics.com
Media Contact: Lynn Granito Berry & Company
Public Relations +1 (212) 253-8881 lgranito@berrypr.com
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to secure licenses for
any technology that may be necessary to commercialize our products;
the ability to achieve or obtain necessary regulatory approvals;
the impact of changes in the financial markets and global economic
conditions; and other risks as may be detailed from time to time in
the Company's Annual Reports on Form 10-K and other reports filed
by the Company with the Securities and Exchange Commission. The
Company undertakes no obligations to make any revisions to the
forward-looking statements contained in this release or to update
them to reflect events or circumstances occurring after the date of
this release, whether as a result of new information, future
developments or otherwise.
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024